MedTrace Logo

Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets

NCT04693039 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-01-03

No results posted yet for this study

Summary

1. To evaluate the safety and tolerability of Phenlarmide tablets in patients with Parkinson's disease in the early and middle stages.
2. To evaluate the pharmacokinetics of Phenlarmide tablets in patients with Parkinson's disease.
3. To explore the efficacy of Phenlarmide tablets in the treatment of early and mid-term Parkinson's disease.

Conditions

  • Parkinson Disease

Interventions

DRUG

Phenlarmide

Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.

DRUG

Placebo

Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.

Sponsors & Collaborators

  • Xuanwu Hospital, Beijing

    collaborator OTHER

  • Shijiazhuang Yiling Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • biao chen · Xuanwu Hospital, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2021-10-29
Completion
2021-10-29

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04693039 on ClinicalTrials.gov